MARKET

VSTM

VSTM

Verastem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.465
-0.125
-4.83%
Closed 17:53 04/03 EDT
OPEN
2.500
PREV CLOSE
2.590
HIGH
2.670
LOW
2.425
VOLUME
872.76K
TURNOVER
--
52 WEEK HIGH
3.490
52 WEEK LOW
0.8300
MARKET CAP
365.83M
P/E (TTM)
-1.2319
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VSTM stock price target is 4.083 with a high estimate of 6.00 and a low estimate of 2.750.

EPS

VSTM News

More
  • Earnings Estimates Moving Higher for Verastem (VSTM): Time to Buy?
  • Zacks · 6d ago
  • Verastem Oncology: An Undervalued KRAS Oncology Play
  • Seeking Alpha - Article · 03/30 07:45
  • Top Drug Stocks Under $5
  • MotleyFool.com · 03/26 11:36
  • The Best Stocks To Buy - 'Is It Over?' Edition
  • Seeking Alpha - Article · 03/20 20:24

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About VSTM

Verastem, Inc., is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. It is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma.
More

Webull offers kinds of Verastem Inc stock information, including NASDAQ:VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions.